We are live on
!
Find out more
AR
Advisory Research Portfolio holdings
AUM
$813M
1-Year Est. Return
36.71%
This Fund
S&P 500
This Quarter
Est. Return
+7.07%
1 Year Est. Return
+36.71%
3 Year Est. Return
+123.04%
5 Year Est. Return
+262.63%
10 Year Est. Return
+840.35%
AUM
$1.02B
AUM Growth
-$1.32M
(-0.13%)
Cap. Flow
-$27.2M
Cap. Flow
% of AUM
-2.65%
Top 10 Holdings %
Top 10 Hldgs %
36.57%
Holding
447
New
77
Increased
110
Reduced
140
Closed
93
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Equinor
EQNR
|
+$9.87M |
| 2 |
Microsoft
MSFT
|
+$9.79M |
| 3 |
Zurn Elkay Water Solutions
ZWS
|
+$8.79M |
| 4 |
ERF
Enerplus Corporation
ERF
|
+$6.71M |
| 5 |
EXE
Expand Energy Corp
EXE
|
+$5.12M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DEN
Denbury Inc.
DEN
|
+$28.4M |
| 2 |
Antero Resources
AR
|
+$22.5M |
| 3 |
Imperial Oil
IMO
|
+$11.8M |
| 4 |
AbbVie
ABBV
|
+$9.22M |
| 5 |
Danaos Corp
DAC
|
+$8.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 35.09% |
| 2 | Technology | 13.02% |
| 3 | Healthcare | 11.46% |
| 4 | Industrials | 9.72% |
| 5 | Financials | 8.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Supernus Pharmaceuticals
SUPN
$2.68B
| $905K | 0.09% |
26,724
+93
| +0.3% | +$3.03K |
|
177
Warby Parker
WRBY
$3.01B
| $853K | 0.08% |
+63,923
| New | +$851K |
|
|
ACCD
178
DELISTED
Accolade Inc
ACCD
| $826K | 0.08% |
+72,345
| New | +$788K |
|
179
Fidelity National Financial
FNF
$13.9B
| $821K | 0.08% |
23,584
-457
| -2% | -$17.1K |
|
180
Domino's
DPZ
$11B
| $810K | 0.08% |
2,612
-588
| -18% | -$223K |
|
|
NETC
181
DELISTED
Nabors Energy Transition Corp.
NETC
| $807K | 0.08% |
80,320
-7,060
| -8% | -$70.9K |
|
|
LGVC
182
DELISTED
LAMF Global Ventures Corp. I Class A Ordinary Shares
LGVC
| $803K | 0.08% |
79,540
-55,310
| -41% | -$554K |
|
183
MGIC Investment
MTG
$6.27B
| $789K | 0.08% |
61,578
+20,573
| +50% | +$288K |
|
184
Fidus Investment
FDUS
$737M
| $788K | 0.08% |
45,879
-1,154
| -2% | -$21.9K |
|
185
AbCellera Biologics
ABCL
$1.62B
| $768K | 0.08% |
77,682
-2,185
| -3% | -$24K |
|
186
Blackstone
BX
$104B
| $757K | 0.07% |
9,050
| – | – |
|
187
Krystal Biotech
KRYS
$9.88B
| $754K | 0.07% |
10,819
-5,022
| -32% | -$363K |
|
|
EVRI
188
DELISTED
Everi Holdings
EVRI
| $746K | 0.07% |
46,020
+11,749
| +34% | +$216K |
|
189
Inspired Entertainment
INSE
$177M
| $745K | 0.07% |
84,358
+26,467
| +46% | +$273K |
|
190
Simulations Plus
SLP
$371M
| $744K | 0.07% |
+15,325
| New | +$895K |
|
191
Iron Mountain
IRM
$38.2B
| $743K | 0.07% |
16,901
| – | – |
|
192
Saratoga Investment
SAR
$309M
| $742K | 0.07% |
35,721
+500
| +1% | +$12K |
|
193
EXL Service
EXLS
$4.23B
| $733K | 0.07% |
24,855
+10,855
| +78% | +$354K |
|
194
Chesapeake Utilities
CPK
$3.26B
| $731K | 0.07% |
6,339
-58
| -0.9% | -$7.51K |
|
195
Bank of America
BAC
$435B
| $719K | 0.07% |
+23,822
| New | +$796K |
|
196
Ginkgo Bioworks
DNA
$481M
| $715K | 0.07% |
5,729
+1,006
| +21% | +$120K |
|
|
TE
197
T1 Energy
TE
$1.4B
| $707K | 0.07% |
+49,642
| New | +$555K |
|
198
Trinity Capital
TRIN
$1.55B
| $693K | 0.07% |
55,297
+934
| +2% | +$13.8K |
|
199
Barings BDC
BBDC
$862M
| $691K | 0.07% |
83,590
-3,615
| -4% | -$34.9K |
|
|
BRSL
200
Brightstar Lottery PLC
BRSL
$1.91B
| $691K | 0.07% |
43,761
-528
| -1% | -$9.88K |
|
Similar funds
VFG
SLG
KCP
UAG
PS
CICI
RPAM
BBI
Advisory Research's Q3 2022 Portfolio in Review
As of Q3 2022, Advisory Research held 447 positions worth $1.02B, down 0.13% from $1.02B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Advisory Research's Q3 2022 filing shows 77 new, 110 increased, 140 reduced and 93 closed positions. Its largest new stake was Velo3D, Inc.: 38,954 shares worth $5.37M. The largest sale was Denbury Inc., an estimated $28.4M.
By sector, the portfolio is most concentrated in Energy at 35% of assets, down from 36% a quarter earlier, followed by Technology and Healthcare.
- Advisory Research's largest Q3 2022 buy was Velo3D, Inc.: 38,954 shares worth $5.37M.
- Advisory Research added most to Equinor in Q3 2022, an estimated $9.87M increase.
- Advisory Research's biggest Q3 2022 reduction was Denbury Inc., cutting an estimated $28.4M.
- Advisory Research fully exited Imperial Oil in Q3 2022, selling an estimated $11.8M.
- Advisory Research's ten largest holdings make up 37% of its $1.02B portfolio in Q3 2022.
- Advisory Research opened 77 new positions and closed 93 in Q3 2022.
- Advisory Research's portfolio value fell 0.13% quarter-over-quarter to $1.02B.
Based on Advisory Research's 13F filing for Q3 2022, filed 15 Nov 2022.